Current approaches to therapy for indolent non-Hodgkin's lymphoma.
Progress in the treatment of indolent non-Hodgkin's lymphoma has been slow and the disease remains incurable despite the relatively long median survival of patients. Decades of clinical trials resulted in standard chemotherapy regimens that produced relatively identical results. Two recent events, however, offer great optimism for future therapeutic progress. First, our understanding of the biology and immunology of lymphoid malignancies has increased remarkably. Second, there are a large number of new and unique chemotherapeutic and biological agents entering into clinical trials.
Cheson
B D
BD
Medicine Section, National Cancer Institute, Bethesda, Maryland, USA.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D008228:Lymphoma, Non-Hodgkin / Q000473:pathology / Q000628:therapy*; D012008:Recurrence
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D016898:Interferon-alpha